CDK6 and acute lymphoblastic leukemia: To further confirm the association between BRD4 and these targets, we used CRISPR to knock out BRD4 in SUP-T1 and KOPT-K1 T-ALL cell lines (Supplementary Fig. 1A) and observed low expression of Myc and CD44 as well as that of CDK4 and CDK6 (Fig. 1D).